Researchers and Community advocates under the aegis of the New HIV Vaccines and Microbicide Advocacy Society (alias NHVMAG) have expressed disappointment over recently released results that showed that Carraguard, a microbicide candidate undergoing Phase 3 trials   failed to effectively protect women against the risk of HIV infection.Population Council, an international non-profit research institution had tested Carraguard, (a microbicide candidate developed as an odorless, clear gel made from carrageenan, a derivative of seaweed for its) effectiveness in a study conducted between 2004-2007. The study enrolled 6,202 women participants in South Africa. Trial results showed that the product was safe and acceptable to women, but did not reduce their risk of acquiring HIV.Coordinator of NHVMAS, Dr Morenike Ukpong noted that result of the Carraguard study comes as a disappointment to the Nigerian advocates who have continued to wait for good news from the field

We applaud the efforts of the researchers at completing the first large-scale effectiveness microbicide trial. We also appreciate the efforts the researchers are making in ensuring transparent communication with trial participants and with African stakeholders about the trial. We also are aware of the hard work of the trial site staff at ensuring effective community participation in the Carraguard study and this we find exemplary.

NHVMAS and the community of Nigerian advocates continue to applaud the current partnership observed between researchers and the community: Dr Bode-Law Faleyimu of NHVMAG noted that “this is truly an effort at true stakeholders involvement and teamwork. If this mutual respect, sharing and involvement continues, we believe we will see less futile research and more successful trials in the future

Ukpong however noted that the disappointment on the part of the advocates only reinforces the need to invest expediently in future microbicide researches.. Quoting Lori Heise of the Global Campaign for Microbicides a leading US based Microbicides Advocacy Organization,  New drug development is always a long term struggle and typically hundreds of product leads fail for every one that succeeds, but discouragement is a luxury we can’t afford. Ukpong noted  that “Our  responsibility now is to learn as much as possible from this trial to inform and guide future research, improve future trials, better predict efficacy and understand how best to partner with communities and improve the standard of care offered to participants.

Nigeria had hosted two phase III microbicide trials in the immediate past (SAVVY and CS3). The disappointing results from the two studies has however not dampened the , enthusiasm of researchers and advocates  who are hopeful that other ongoing global  research efforts will yield positive results for a safe, effective and affordable microbicide in the not too distant future .

Though the HIV prevalence in Nigeria is decreasing based on the 2001, 2003 and antenatal clinic Sentinel Survey results from the Federal Ministry of Health, the statistics still indicate that women are worse affected by the epidemic.

Vaginal microbicides which are being developed as a female-initiated method for reducing male-to-female transmission of HIV and possibly other sexually transmitted infections (STI) when used during sex, would therefore be a welcome intervention that will boost the quality of currently existing HIV prevention tools in Nigeria

The New HIV Vaccine and Microbicide Advocacy Society (alias NHVMAG) is a coalition of stakeholders (advocates, researchers, policy makers, media persons, academia and ethicists) engaged directly and indirectly with New HIV Prevention Technology Research and Development in Nigeria

www.nhv-mag.org

Contact: Morenike Ukpong,

+ 234 803 2459 256;

toyinukpong@yahoo..co.uk